USANA Health Sciences (NYSE:USNA) Upgraded at Wall Street Zen

USANA Health Sciences (NYSE:USNA) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Several other equities analysts have also recently commented on USNA. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $36.00.

USANA Health Sciences Price Performance

NYSE USNA opened at $21.69 on Friday. The firm has a market capitalization of $396.46 million, a price-to-earnings ratio of 39.43, a price-to-earnings-growth ratio of 0.81 and a beta of 0.67. The company has a 50 day simple moving average of $20.71 and a 200-day simple moving average of $23.53. USANA Health Sciences has a 52-week low of $18.48 and a 52-week high of $38.32.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.19. The firm had revenue of $226.20 million for the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. On average, analysts predict that USANA Health Sciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On USANA Health Sciences

A number of large investors have recently bought and sold shares of USNA. Pzena Investment Management LLC increased its position in USANA Health Sciences by 1.2% during the third quarter. Pzena Investment Management LLC now owns 1,212,588 shares of the company’s stock worth $33,407,000 after buying an additional 14,328 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of USANA Health Sciences by 1.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,147,323 shares of the company’s stock worth $22,522,000 after acquiring an additional 21,793 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of USANA Health Sciences by 5.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,069,032 shares of the company’s stock valued at $29,452,000 after acquiring an additional 57,249 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in shares of USANA Health Sciences by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 915,049 shares of the company’s stock valued at $25,210,000 after acquiring an additional 17,318 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in USANA Health Sciences in the 4th quarter worth approximately $11,485,000. 54.25% of the stock is currently owned by institutional investors.

About USANA Health Sciences

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.